Hui Feng, MD, PhD

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Cancer Research: Dr. Feng is Director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia, Neuroblastoma and Breast Cancer. The research strategy of Dr. Feng’s research is to combine the analysis of human cancer cells with the genetic and imaging capacities of the zebrafish system.

Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify novel genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers and to characterize their molecular relevance to MYC.

The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.

Publications

  • Published 4/2/2024

    AI is a viable alternative to high throughput screening: a 318-target study. Sci Rep. 2024 Apr 02; 14(1):7526. PMID: 38565852.

    Read at: PubMed

  • Published 3/15/2024

    Qin X, Lam A, Zhang X, Sengupta S, Iorgulescu JB, Ni H, Das S, Rager M, Zhou Z, Zuo T, Meara GK, Floru AE, Kemet C, Veerapaneni D, Kashy D, Lin L, Lloyd K, Kwok L, Smith KS, Nagaraju RT, Meijers R, Ceol C, Liu CT, Alexandrescu S, Wu CJ, Keskin DB, George RE, Feng H. CKLF instigates a "cold" microenvironment to promote MYCN-mediated tumor aggressiveness. Sci Adv. 2024 Mar 15; 10(11):eadh9547. PMID: 38489372.

    Read at: PubMed

  • Published 2/7/2024

    Xiao B, Landesman-Bollag E, Feng H. What value do zebrafish have to anticancer drug discovery? Expert Opin Drug Discov. 2024 Apr; 19(4):369-375. PMID: 38327017.

    Read at: PubMed

  • Published 3/23/2023

    Laroche FJF, Li S, Shen N, Hwang SK, Nguyen G, Yu W, Wong CK, Quinton RJ, Berman JN, Liu CT, Singh A, Ganem NJ, Thiagalingam S, Feng H. S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720. Cells. 2023 Mar 23; 12(7). PMID: 37048053.

    Read at: PubMed

  • Published 6/16/2022

    Wang Y, Shen N, Spurlin G, Korm S, Huang S, Anderson NM, Huiting LN, Liu H, Feng H. a-Ketoglutarate-Mediated DNA Demethylation Sustains T-Acute Lymphoblastic Leukemia upon TCA Cycle Targeting. Cancers (Basel). 2022 Jun 16; 14(12). PMID: 35740646.

    Read at: PubMed

View All 51 Publications:   View Full Profile in BUMC

Other Positions

  • Member, BU-BMC Cancer Center
    Boston University
  • Member, Genome Science Institute
    Boston University
  • Graduate Faculty (Primary Mentor of Grad Students)
    Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

Websites

Education

  • Beijing Medical University, MD
  • University of Georgia, PhD
  • Peking Union Medical College, MS

View all profiles